Stay updated on Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page
- Check6 days agoChange DetectedThe page's revision tag was updated from v3.6.4 to v3.6.5, indicating a new release of the page template. This is a technical update with no indicated changes to study details or visible content.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check21 days agoChange DetectedThe page revision changed from v3.6.3 to v3.6.4, reflecting a minor backend/update with no visible changes to study content or layout.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check49 days agoChange DetectedThe page now displays a new site revision label, Revision: v3.6.3, replacing the previous Revision: v3.6.0. This indicates a software update to the site rather than changes to the clinical study information shown on the page.SummaryDifference0.1%

- Check63 days agoChange DetectedThe investigators section was updated to include Hiroaki Akamatsu and adjust institution references. New help/navigation items were added (How to Read a Study Record, Common Questions, How to Join a Study), the Intervention/Treatment label formatting was updated, and the revision tag changed from v3.5.5 to v3.6.0.SummaryDifference2%

- Check70 days agoChange DetectedThe page now shows Revision: v3.5.5, indicating a new site revision. This replaces the previous Revision: v3.5.4 and reflects a minor platform update.SummaryDifference0.1%

- Check92 days agoChange DetectedRevision: v3.5.4 was added to the page, replacing the previous v3.5.3. This indicates a site software/version update for the ClinicalTrials.gov page, with no evident changes to the study's details or eligibility criteria.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.